BioSpace News Archive

Nuvo Pharmaceuticals ® Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Jesse Ledger , Miravo’s President & Chief Executive Officer will be presenting at the Q2 Virtual Investor Summit.

Axcella Announces Initiation of EMMPACT SM Phase 2b Clinical Trial of AXA1125 Initial clinical sites activated and patient screening underway Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH)

Biosero, Inc., developer of automation solutions that enable laboratories to make better decisions in less time using more data, today announced two key hires as it expands commercial operations. Ryan Bernhardt joins the company as Chief Commercial Officer, and Ruth Petersen is named Director of Marketing. “At Biosero, ou

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the granting of a National Institutes of Health (“NIH”) award to the University of California San Diego School of Medicine for the proposal entitled, “Renal Molecular Imaging of Mesangial Cell Function with Tc-99m-Tilmanocept.”

Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds.

M6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24 th Annual Meeting - Preclinical data provide proof of concept for M002 to restore cellular uptake and lysosomal delivery and attenuate phenotype in mouse models of mucolipidosis type II -

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2021 (“Q1-F2021”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted.

MediPharm Labs Corp. a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release first quarter financial results for the three month period ended March 31, 2021 before markets open on Monday, May 17, 2021.

Biom Pharmaceuticals’ VagiBiom® feminine product is now available in all Walmart stores. This novel microbiome-focused formulation was presented at Walmart’s Made in USA Open Call competition in October 2020 and got selected for launch in all Walmart stores.